ReviewJournal of fungi (Basel, Switzerland)2022
Quantifying Deaths from Aspergillosis in HIV Positive People.
Review in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.American journal of respiratory and critical care medicine · 2026Article
- Pulmonary cavitation as a dominant prognostic indicator in tuberculosis complicated by chronic pulmonary aspergillosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Identification of Clinical Characteristics and Risk Factors of Invasive Pulmonary Aspergillosis in Patients with Acquired Immunodeficiency Syndrome: A Retrospective Study.Infection and drug resistance · 2026Article
- Fungal Infection in HIV-Infected Patients-Is It Still a Challenge?Journal of clinical medicine · 2025Review
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Urbanisation and Lockdown Impact on Airborne Fungal Communities in Tropical Landscapes: A Comparative Study of Urban and Peri-Urban Environments.Environmental microbiology reports · 2025Article
- Review
- Co-Infection of Pulmonary Aspergillosis and Cryptococcal Meningitis in an HIV-Positive Patient: A Case Report.Case reports in infectious diseases · 2025Article
- Identifying Gaps in the International Consensus Case Definitions for Invasive Aspergillosis: A Review of Clinical Cases Not Meeting These Definitions.Open forum infectious diseases · 2024Article
- Blood microbiota in HIV-infected and HIV-uninfected patients with suspected sepsis detected by metagenomic next-generation sequencing.BMC infectious diseases · 2024Article
- Review
- Frequency of fungal pathogens in autopsy studies of people who died with HIV in Africa: a scoping review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Article
- Chronic pulmonary Aspergillosis in a patient with poorly controlled diabetes: A case report and literatures review.Respirology case reports · 2024Article
- Fungal infections in Sudan: An underestimated health problem.PLoS neglected tropical diseases · 2023Article
- Burden of fungal infections in Kenya.Mycology · 2023Article
- Regulation of lung inflammation by adiponectin.Frontiers in immunology · 2023Review
- Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges.Therapeutic advances in infectious diseaseReview
- Re-estimation of the burden of serious fungal diseases in Uganda.Therapeutic advances in infectious diseaseArticle
- Isolated renal and urinary tract aspergillosis: a systematic review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus spp. are ubiquitous and cause severe infections in immunocompromised patients. Less is known about its incidence and prognosis in patients with HIV/AIDS. We reviewed the mortality of invasive aspergillosis in HIV/AIDS patients. Pubmed, Embase and Medline databases were used to search for articles. Studies were excluded if they contained other aspergillosis risk factors, no original or patient survival data or were not in English. From 747 articles published, 54 studies and case reports were identified following reading, published between 1985 and 2021, with 54% papers prior to 2000 reporting 853 patients from 16 countries, none from Africa. 707 (83%) patients died with an average time from diagnosis to death of 77.5 days. Postmortem diagnosis was seen in 21% of deaths recorded. A national series from France of 242 cases of invasive aspergillosis diagnosed in life recorded a 3 month mortality of 68% pre-ART, falling to 31% after introduction of ART and voriconazole. CD4 count was recorded in 39 studies and ranged from 2 to >1000 cells/mm3; only 8 patients (1.8%) had a CD4 > 100 cells/mm3. Aspergillosis occurs in patients with HIV/AIDS and associated with high mortality but its slow progression should allow diagnosis and treatment with improved outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.